Iloperidone: A novel atypical antipsychotic for the treatment of schizophreniaJune 1st 2008
Iloperidone, a new-generation atypical antipsychotic, is currently under investigation for the treatment of schizophrenia. In 4 separate phase 3 trials, iloperidone has demonstrated efficacy in treating schizophrenia, with total Positive and Negative Symptom Scale (PANSS) scores decreasing by a range of 8 to 14 points depending on the iloperidone dose.
Lubiprostone (Amitiza): Chloride channel activator approved for the treatment of irritable bowel syndrome with constipationJune 1st 2008
New indication: Lubiprostone (Amitiza), a chloride channel activator, was approved on April 29, 2008, for the treatment of irritable bowel syndrome with constipation (IBS-C) in women aged at least 18 years.
Certolizumab pegol (Cimzia): Tumor necrosis factor blocker approved for the treatment of moderate-to-severe Crohn's diseaseJune 1st 2008
New biologic: Certolizumab pegol (Cimzia), a tumor necrosis factor blocker, was approved on April 22, 2008, for the reduction of the signs and symptoms of Crohn's disease and the maintenance of clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
High- and low-tech solutions to reduce the incidence of hospital-acquired infections and antibiotic resistanceMay 1st 2008
Approximately 1.7 million healthcare-associated infections (HAIs) occur in US hospitals each year. These HAIs, which include pneumonia, bloodstream infections (BSIs), and urinary tract infections (UTIs), account for approximately 99,000 deaths and $5 billion in additional healthcare costs.
International Stroke Conference 2008: EPITHET: Patients who suffer a stroke and have a perfusion-diffusion mismatch may benefit from tPA beyond the 3-hour windowApril 1st 2008
Data from EPITHET presented at the International Stroke Conference 2008 demonstrates that extending the standard 3-hour window for tPA could benefit patients who suffer a stroke and have a perfusion-diffusion mismatch.
Off-label stent use: DES associated with equal safety risks and reduced risk of repeat PCI compared with BMSApril 1st 2008
Study shows no significant differences in safety risks between off-label use of drug-eluting stents (DES) and off-label use of bare-metal stents (BMS) and a decreased risk of repeat PCI with use of off-label BMS.
Desvenlafaxine (Pristiq): Selective serotonin and norepinephrine reuptake inhibitor approved for the treatment of major depressive disorderApril 1st 2008
NME: Desvenlafaxine (Pristiq), a selective serotonin and norepinephrine reuptake inhibitor was recently approved for the treatment of major depressive disorder.
Bevacizumab plus paclitaxel can slow breast cancer progression but does not improve overall survivalMarch 11th 2008
Adding bevacizumab to treatment with paclitaxel does not prolong overall survival among patients with metastatic breast cancer; however, the combination therapy is associated with a significant improvement in progression-free survival, according to the results of a trial published in the New England Journal of Medicine (NEJM).
Etravirine: A non-nucleoside reverse transcriptase inhibitor for the treatment of resistant HIV-1 infectionMarch 1st 2008
Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that was approved January 18, 2008, for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in antiretroviral treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to NNRTIs and other antiretroviral agents.
Natalizumab (Tysabri): Monoclonal antibody approved for the treatment of moderate-to-severe Crohn's diseaseFebruary 1st 2008
FDA-related information through February 2008 on Fluvoxamine extended-release capsules, dalbavancin, bazedoxifene, HPV vaccine (Cervarix), valrubicin, motexafin gadolinium, COL-003, CDX-110, sugammadex, mecaserim rinfabate, A-001, beclomethasone, clobazam, fludarabine tablets, JZP-8, and AST-120
Equivalent dosing of irbesartan, valsartan, and losartan identified through formulary switch at a Veterans Affairs medical centerJanuary 1st 2008
Until 2005, irbesartan was the only ARB available on the Veterans Affairs (VA) healthcare system's national formulary. In 2005, irbesartan was removed from the formulary and was replaced with valsartan and losartan. For those patients who were to continue ARB therapy via a switch to either losartan or valsartan, dosing guidelines were created by the Veterans Integrated System Network 7 to facilitate the change. These guidelines suggested that patients taking irbesartan 150 mg once daily be treated with either valsartan 80 mg or losartan 50 mg once daily and that patients taking irbesartan 300 mg once daily be treated with either valsartan 160 mg or losartan 100 mg once daily. To determine if the dosing guidelines resulted in equal antihypertensive effectiveness, we carried out a retrospective chart review, examining the cases of 86 patients at the William Jennings Bryan Dorn VA Medical Center in Columbia, South Carolina, who had switched from irbesartan to either losartan or valsartan.